Picture of Medicus Pharma logo

MDCX Medicus Pharma Share Price

0.000.00%
ca flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro CapSucker Stock

Momentum

Relative Strength (%)
1m+35.41%
3m+87.28%
6m+20.62%
1yr-6.82%
Volume Change (%)
10d/3mn/a
Price vs... (%)
52w High-22.24%
50d MA+29.2%
200d MA+26.6%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-313.17%
Return on Equity-335.15%
Operating Marginn/a

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202431st Dec 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of Medicus Pharma EPS forecast chart

Profile Summary

Medicus Pharma Ltd. is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutic assets. Its subsidiaries include SkinJect, Inc, and Medicus Pharma Inc. The Company’s wholly owned subsidiary, SkinJect, Inc (SkinJect), is focused on commercializing a novel, non-invasive treatment for basal cell skin cancer using a patented dissolvable microneedle patch to deliver chemotherapeutic agent to eradicate tumor cells. The Company’s wholly owned subsidiaries are focused on the development of a drug delivery system using a dissolvable microneedle array for the treatment of certain skin cancers. The Company investigates opportunities across all therapeutic areas where an unmet need exists for improved patient safety and efficacy. The Company is actively exploring expanding its drug development pipeline through qualified and accretive acquisitions and partnerships.

Directors

    Last Annual
    December 31st, 2023
    Last Interim
    September 30th, 2024
    Incorporated
    April 30th, 2008
    Public Since
    October 11th, 2023
    Sector
    Pharmaceuticals
    Industry
    Healthcare
    Exchange
    ca flag iconTSX Venture Exchange
    Shares in Issue
    10,846,780

    MDCX Share Price Performance

    Upcoming Events for MDCX

    Similar to MDCX

    Picture of Aequus Pharmaceuticals logo

    Aequus Pharmaceuticals

    ca flag iconTSX Venture Exchange

    Picture of Arch Biopartners logo

    Arch Biopartners

    ca flag iconTSX Venture Exchange

    Picture of Biosyent logo

    Biosyent

    ca flag iconTSX Venture Exchange

    Picture of Cytophage Technologies logo

    Cytophage Technologies

    ca flag iconTSX Venture Exchange

    Picture of Decibel Cannabis logo

    Decibel Cannabis

    ca flag iconTSX Venture Exchange

    FAQ